Mechanistic insights into CDCA gene family-mediated glioblastoma progression: implications for diagnosis, prognosis, and therapeutic targeting

Hereditas, Journal Year: 2025, Volume and Issue: 162(1)

Published: March 20, 2025

Abstract Background Glioblastoma (GBM) is a highly aggressive brain tumor characterized by poor prognosis and limited therapeutic options. Understanding the molecular mechanisms driving GBM progression essential for developing more effective diagnostic approaches. Specifically, investigating Cell Division Cycle-Associated (CDCA) genes offers new perspectives on cell cycle regulation proliferation of cells, which are key factors in growth resistance to treatment. These have not been extensively studied GBM, making them promising area targeted research potential interventions. This project was launched elucidate pathogenic, diagnostic, roles CDCA GBM. Methodology Total RNA extracted from lines followed RT-qPCR analyze expression genes. The validation, prognostic significance, mutational analysis were performed using various databases. Functional assays, including gene knockdown, colony formation, proliferation, wound healing, conducted U87MG cells assess role CDCA7 CDCA8 Results 12 6 normal revealed significant overexpression these ROC curve demonstrated excellent potential, with AUC values 1 most indicates that effectively distinguishes cells. Validation additional TCGA data confirmed upregulation tumors, association cancer-related pathways. Survival showed higher correlated patients. Mutation, CNV, methylation analyses alterations genes, further supporting their Additionally, linked immune modulation cycle-related functions, suggesting involvement evasion proliferation. Knockdown experiments reduction migration, highlighting as targets. Conclusion Overall, our findings suggest could serve both biomarkers targets

Language: Английский

---

Identification and functional characterization of key biomarkers in diffuse large B-cell lymphoma: emphasis on STYX as a prognostic marker and therapeutic target

Hereditas, Journal Year: 2025, Volume and Issue: 162(1)

Published: March 24, 2025

Abstract Diffuse large B-cell lymphoma (DLBC) is the most common subtype of non-Hodgkin lymphoma, characterized by its aggressive nature and poor prognosis in advanced stages. Despite advances treatment, molecular mechanisms driving DLBC progression remain incompletely understood, necessitating identification novel biomarkers for diagnosis prognosis. In this study, we analyzed two publicly available datasets (GSE32018 GSE56315) from Gene Expression Omnibus database (GEO) to identify overlapping differentially expressed genes (DEGs). Later on, a comprehensive silico vitro methodology was adopted decipher role DEGs DLBC. analysis GSE32018 GSE56315 identified five gene: SP3, CSNK1A1, STYX, SIRT5, MGEA5. validation using GEPIA2 confirmed upregulation downregulation MGEA5 tissues compared normal controls. Furthermore, mutational revealed that CSNK1A1 only gene among these exhibit mutations, with 2.7% mutation frequency patients. Methylation highlighted negative correlation between methylation levels mRNA expression, while survival high STYX expression as significantly associated poorer overall Functional assays demonstrated knockdown U2932 cells led reduced cell proliferation, colony formation, enhanced wound healing, indicating STYX’s pivotal migration. Additionally, enrichment involvement key biological processes, including intracellular trafficking myeloid progenitor differentiation. These findings emphasize potential therapeutic targets DLBC, particularly highlighting promising prognostic marker target intervention.

Language: Английский

---

Roles of anoikis in hepatocellular carcinoma therapy and the assessment of anoikis-regulatory molecules as therapeutic targets

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: April 4, 2025

Language: Английский

---

The pathogenesis mechanism and potential clinical value of lncRNA in gliomas

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: July 5, 2024

Abstract Glioma is the most common malignant tumor in central nervous system, and its unique pathogenesis often leads to poor treatment outcomes prognosis. In 2021, World Health Organization (WHO) divided gliomas into five categories based on their histological characteristics molecular changes. Non-coding RNA a type of that does not encode proteins but can exert biological functions at level, long non-coding (lncRNA) with length exceeding 200 nt. It controlled by various transcription factors plays an indispensable role regulatory processes cells. Numerous studies have confirmed dysregulation lncRNA critical pathogenesis, progression, malignancy gliomas. Therefore, this article reviews proliferation, apoptosis, invasion, migration, angiogenesis, immune regulation, glycolysis, stemness, drug resistance changes caused gliomas, summarizes potential clinical significance

Language: Английский

---

Regulatory RNAs: role as scaffolds assembling protein complexes and their epigenetic deregulation

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2024, Volume and Issue: 5(4), P. 841 - 876

Published: July 22, 2024

Recently, new data have been added to the interaction between non-coding RNAs (ncRNAs) and epigenetic machinery. Epigenetics includes enzymes involved in DNA methylation, histone modifications, RNA mechanisms underlying chromatin structure, repressive states, active states operating transcription. The main focus is on long ncRNAs (lncRNAs) acting as scaffolds assemble protein complexes. This review does not cover RNA's role sponging microRNAs, or decoy functions. Several lncRNAs were shown regulate activation repression by interacting with Polycomb complexes mixed-lineage leukemia (MLL) activating Various groups reported enhancer of zeste homolog 2 (EZH2) interactions regulatory RNAs. Knowledge function these opens perspective develop therapeutics for cancer treatment. Lastly, interplay epitranscriptomic modifications cancers paves way targets therapy. approach inhibit epitrascriptomics-regulated may bring compounds therapeuticals various types cancer.

Language: Английский

---

Emerging discoveries on the role of TRIM14: from diseases to immune regulation

Cell Death Discovery, Journal Year: 2024, Volume and Issue: 10(1)

Published: Dec. 24, 2024

Abstract TRIM14 is an important member of the TRIM family and widely expressed in a variety tissues. Like other members family, also involved ubiquitination modifications. was initially reported as interferon-stimulated gene (ISG). In recent years, many studies have focused on regulatory role signaling pathways such PI3K/Akt, NF-κB, cGAS/STING revealed its mechanism action pathophysiological processes, regulation has attracted interest researchers new direction for treatment various diseases. However, there are no reviews this paper, we will describe structure TRIM14, review cancer, cardiovascular disease, cervical spondylosis, inflammation antiviral immunity, provide outlook future research directions.

Language: Английский

---

Unveiling the role of RNA methylation in glioma: Mechanisms, prognostic biomarkers, and therapeutic targets

Cellular Signalling, Journal Year: 2024, Volume and Issue: 124, P. 111380 - 111380

Published: Sept. 3, 2024

Language: Английский

---